How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lansoprazole-bismuth-subsalicylate-metronidazole-tetracycline.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline (Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination therapy / H. pylori eradication regimen. Area: Gastroenterol

phase 3 Antibiotic combination therapy / H. pylori eradication regimen H. pylori (multiple targets: bacterial cell membrane, DNA, protein synthesis machinery) Gastroenterology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline (Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline) — Soroka University Medical Center. This quadruple therapy combination eradicates Helicobacter pylori by reducing gastric acid, disrupting bacterial cell membranes, and inhibiting bacterial protein synthesis and DNA replication.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline TARGET	Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline	Soroka University Medical Center	phase 3	Antibiotic combination therapy / H. pylori eradication regimen	H. pylori (multiple targets: bacterial cell membrane, DNA, protein synthesis machinery)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination therapy / H. pylori eradication regimen class)

Soroka University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline — Competitive Intelligence Brief. https://druglandscape.com/ci/lansoprazole-bismuth-subsalicylate-metronidazole-tetracycline. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab